Why Repligen Is Ready to Rebound
With that in mind, let's take a closer look at Repligen and see what CAPS investors are saying about the stock right now.
Waltham, Mass. (1981)
CEO Dr. Walter Herlihy
Trailing-12-Month Return on Equity
$47.9 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 333 members who have rated Repligen believe the stock will outperform the S&P 500 going forward.
I missed the bump in Repligen's share price in the spring because I set an outperform threshold of 6 that never quite clicked. The stock has been pulling back over the last month but I still like the growing bioprocessing revenues, courtesy of the excellent acquisition of Novozymes Biopharma Sweden AB in 2011. Repligen still has to outgrow a well-deserved reputation for futility but if they can successfully transition from drug development into products and services there's still a lot of potential for share price appreciation.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a perfect five-star rating, Repligen may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
The article Why Repligen Is Ready to Rebound originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.